MNG964
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.568
- E2F_TARGETS+0.506
- G2M_CHECKPOINT+0.475
- MYC_TARGETS_V1+0.417
- GLYCOLYSIS+0.315
- UNFOLDED_PROTEIN_RESPONSE+0.297
- MTORC1_SIGNALING+0.286
- MITOTIC_SPINDLE+0.263
- CHOLESTEROL_HOMEOSTASIS+0.251
- DNA_REPAIR+0.204
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.439
- ANGIOGENESIS-0.402
- HEDGEHOG_SIGNALING-0.318
- INTERFERON_ALPHA_RESPONSE-0.317
- BILE_ACID_METABOLISM-0.315
- MYOGENESIS-0.313
- UV_RESPONSE_DN-0.285
- KRAS_SIGNALING_DN-0.278
- INFLAMMATORY_RESPONSE-0.266
- PANCREAS_BETA_CELLS-0.265
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.891 |
| 2 | SRR5088814 | — | — | 0.881 |
| 3 | MNG534 | — | — | 0.876 |
| 4 | 96a00cc6-3880-4f03-a08d-73d284787971 | — | — | 0.867 |
| 5 | SRR11296736 | — | — | 0.862 |
| 6 | MNG332 | — | — | 0.854 |
| 7 | BS_MV6ASWV9 | ATRT | — | 0.853 |
| 8 | 1764b9ab-4f37-47c5-8225-40c574433f40 | — | — | 0.852 |
| 9 | TCGA-DK-A3X2-01A-11R-A22U-07 | — | — | 0.851 |
| 10 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.568 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.506 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.475 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.417 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.315 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.297 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.286 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.263 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.251 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.204 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.201 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.123 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.108 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.099 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.087 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.038 | Inavolisib | — uncovered |
| PEROXISOME | 0.023 | Idelalisib | — uncovered |
| HYPOXIA | 0.006 | Idelalisib | — uncovered |